GB2623078A - Prevention and/or treatment of wound infection - Google Patents
Prevention and/or treatment of wound infection Download PDFInfo
- Publication number
- GB2623078A GB2623078A GB2214521.3A GB202214521A GB2623078A GB 2623078 A GB2623078 A GB 2623078A GB 202214521 A GB202214521 A GB 202214521A GB 2623078 A GB2623078 A GB 2623078A
- Authority
- GB
- United Kingdom
- Prior art keywords
- acnes
- wound
- composition
- supernatant
- infection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010048038 Wound infection Diseases 0.000 title claims abstract description 17
- 230000002265 prevention Effects 0.000 title claims abstract description 8
- 208000027418 Wounds and injury Diseases 0.000 claims abstract description 91
- 206010052428 Wound Diseases 0.000 claims abstract description 90
- 241000186427 Cutibacterium acnes Species 0.000 claims abstract description 88
- 239000000203 mixture Substances 0.000 claims abstract description 48
- 239000006228 supernatant Substances 0.000 claims abstract description 33
- 241000894006 Bacteria Species 0.000 claims abstract description 29
- 230000000975 bioactive effect Effects 0.000 claims abstract description 27
- 208000015181 infectious disease Diseases 0.000 claims abstract description 23
- 238000000034 method Methods 0.000 claims abstract description 18
- 238000009472 formulation Methods 0.000 claims abstract description 16
- 239000002207 metabolite Substances 0.000 claims abstract description 16
- 230000003190 augmentative effect Effects 0.000 claims abstract description 15
- 239000012228 culture supernatant Substances 0.000 claims abstract description 14
- 239000000284 extract Substances 0.000 claims abstract description 14
- 238000004519 manufacturing process Methods 0.000 claims abstract description 10
- 239000006071 cream Substances 0.000 claims abstract description 7
- 239000002674 ointment Substances 0.000 claims abstract description 6
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims abstract description 5
- 208000020154 Acnes Diseases 0.000 claims description 16
- 206010072170 Skin wound Diseases 0.000 claims description 7
- 239000000499 gel Substances 0.000 abstract description 5
- 229940055019 propionibacterium acne Drugs 0.000 abstract description 2
- 241000186216 Corynebacterium Species 0.000 abstract 1
- 239000006041 probiotic Substances 0.000 description 19
- 235000018291 probiotics Nutrition 0.000 description 19
- 230000000529 probiotic effect Effects 0.000 description 14
- 230000004083 survival effect Effects 0.000 description 13
- 244000052769 pathogen Species 0.000 description 9
- 230000001580 bacterial effect Effects 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 210000003491 skin Anatomy 0.000 description 8
- 239000003242 anti bacterial agent Substances 0.000 description 7
- 229940088710 antibiotic agent Drugs 0.000 description 7
- 239000010410 layer Substances 0.000 description 7
- 239000001974 tryptic soy broth Substances 0.000 description 7
- 108010050327 trypticase-soy broth Proteins 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 6
- 208000014674 injury Diseases 0.000 description 6
- 230000001717 pathogenic effect Effects 0.000 description 6
- 230000003115 biocidal effect Effects 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- 244000005714 skin microbiome Species 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 241000181693 Pseudomonas aeruginosa PA14 Species 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 238000009630 liquid culture Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- 230000008733 trauma Effects 0.000 description 4
- 239000006150 trypticase soy agar Substances 0.000 description 4
- 241000238631 Hexapoda Species 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000006161 blood agar Substances 0.000 description 3
- -1 for example Substances 0.000 description 3
- 244000005709 gut microbiome Species 0.000 description 3
- 239000000017 hydrogel Substances 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000001018 virulence Effects 0.000 description 3
- 230000029663 wound healing Effects 0.000 description 3
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000191940 Staphylococcus Species 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000010408 film Substances 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 210000003780 hair follicle Anatomy 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000000416 hydrocolloid Substances 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 230000001418 larval effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 244000039328 opportunistic pathogen Species 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000037314 wound repair Effects 0.000 description 2
- 208000031729 Bacteremia Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241000255896 Galleria mellonella Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 240000006024 Lactobacillus plantarum Species 0.000 description 1
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 1
- 241000736262 Microbiota Species 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 229960005475 antiinfective agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000011810 insulating material Substances 0.000 description 1
- 229940072205 lactobacillus plantarum Drugs 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 238000011218 seed culture Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/36—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing microorganisms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/46—Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/0066—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/00051—Accessories for dressings
- A61F13/00063—Accessories for dressings comprising medicaments or additives, e.g. odor control, PH control, debriding, antimicrobic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00089—Wound bandages
- A61F2013/00157—Wound bandages for burns or skin transplants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7007—Drug-containing films, membranes or sheets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/30—Compounds of undetermined constitution extracted from natural sources, e.g. Aloe Vera
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/34—Materials or treatment for tissue regeneration for soft tissue reconstruction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Materials Engineering (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
A composition comprising Cutibacterium acnes (also known as Propionibacterium acnes or Corynebacterium parvum), C. acnes culture supernatant and/or a bioactive extract or metabolite obtainable from C. acnes culture and/or supernatant for use in a method of medical treatment. The same composition for use in the treatment or prevention of wound infection, a formulation comprising a therapeutically effective amount of the composition in combination with a dermatologically compatible carrier, a method of making the formulation comprising incorporating a therapeutically effective amount of the composition into a dermatologically acceptable carrier, and an augmented wound dressing including the composition or formulation are also included. The wound may be a burn. The infection may be with Gram negative bacteria, preferably Pseudomonas aeruginosa. The carrier may be an ointment, gel or cream.
Description
Intellectual Property Office Application No G132214521 1 RTM Date:17 March 2023 The following terms are registered trade marks and should be read as such wherever they occur in this document: Tegaderm Intellectual Property Office is an operating name of the Patent Office www.gov.uk/ipo PREVENTION AND/OR TREATMENT OF WOUND INFECTION This application relates to prevention and/or treatment of wound infection. In particular it relates to a composition for use in a method of medical treatment, in particular for treating or preventing wound infection.
The NHS spends £5 billion annually in wound care and wound management. The spending is likely to increase year on year due to the pressures of the antibiotic resistance crisis and the routine failure of frontline wound therapeutics.
The use of antibiotics to treat wound infections is limited by the emergence of multidrug or pandrug resistant wound pathogens. This is a particular issue for hospital associated infections which typically have a broad resistance profile. The prophylactic use of antibiotics to prevent wound infection is also perpetuating this problem.
It is known to provide wound dressings augmented with substances (for example, antibiotics or other substances) to prevent or treat wound infection. However, many of the wound dressings that are in clinical use are ineffective against biofilnn-forming pathogens, or they contain compounds such as silver which have antimicrobial properties but can also inhibit or slow wound healing.
The present invention seeks to provide improved prevention and/or treatment of wound infection.
According to an aspect of the present invention, there is provided a composition including Cut/bacterium acnes, Cut/bacterium acnes culture supernatant, and/or a bioactive extract or metabolite obtainable from Cut/bacterium acnes culture and/or supernatant for use in a method of medical treatment.
According to another aspect of the present invention, there is provided a composition including C. acnes, C. acnes culture supernatant, and/or a bioactive extract or metabolite obtainable from C. acnes culture and/or supernatant for use in a method of treating or preventing wound infection.
The C. acnes cells may be live or dead.
The wound may be a burn.
In some embodiments, the C. acnes strain may be Phylotype I. In other embodiments it may be Phylotype II.
The method of medical treatment may be treatment or prevention of infection by Gram-negative bacteria, for example Pseudomonas aeruginosa.
According to another aspect of the present invention, there is provided a formulation for application to a human skin wound including a composition as specified above or a therapeutically effective amount of Cut/bacterium acnes, Cut/bacterium acnes culture supernatant, and/or a bioactive extract or metabolite obtainable from Cut/bacterium acnes culture and/or supernatant in combination with a dernnatologically compatible carrier.
The carrier may be an ointment, a gel, or a cream.
According to another aspect of the present invention, there is provided an augmented wound dressing including a composition or a formulation as specified above.
According to another aspect of the present invention, there is provided a method of making a formulation as specified above, including incorporating a therapeutically effective amount of a composition as specified above, or of Cutibacterium acnes, Cutibacterium acnes culture supernatant, and/or a bioactive extract or metabolite obtainable from Cutibacterium acnes culture and/or supernatant into a dermatologically compatible carrier.
The amount of the composition or of Cutibacterium acnes, Cutibacterium acnes culture supernatant, and/or a bioactive extract or metabolite obtainable from Cutibacterium acnes culture and/or supernatant to be incorporated into the dernnatologically compatible carrier can be determined on the basis of the wound type and its size and depth, and the type of dressing to which it is eventually applied.
According to another aspect of the present invention, there is provided a method of making an augmented wound dressing including applying a composition as specified above or a formulation as specified above to a dressing for treating a skin wound, where applying can mean incorporating, impregnating, saturating, or any other suitable method of introducing the composition or formulation to a skin wound dressing.
According to another aspect of the present invention, there is provided a method of preventing or treating wound infection including applying a composition, a formulation and/or an augmented wound dressing as specified above to a skin wound of a patient in need thereof. The skilled person will appreciate that the dressing will be changed at appropriate intervals until the wound has healed and/or until infection is no longer a risk.
Embodiments of the present invention are described below, by way of example only, with reference to the accompanying drawings, in which: Figures 1 to 5 are schematic illustrations of embodiments of wound dressings; Figure 6 illustrates infection progression in an invertebrate burn wound model; Figure 7 is a graph showing the effect of C. acnes CCUG38584 on P. aeruginosa challenged insect larvae in the model illustrated in Figure 6; Figure 8 is a graph showing the effect of C. acnes CCUG48370 on P. aeruginosa challenged insect larvae in the model illustrated in Figure 6; and Figure 9 is a graph showing the effect of C. acnes CCUG6369 on P. aeruginosa challenged insect larvae in the model illustrated in Figure 6.
S
It is now well established that a healthy gut microbiome plays a key role in human health. However, relatively little work has been carried out on the role the human skin microbiome plays in maintaining health. Over the last couple of years, the capacity to use probiotics to promote wound healing has been demonstrated in vitro and in vivo. The majority of these studies have focused on gut bacteria, such as Lactobacilli and bifidobacteria, with clinical trials taking place for Lactobacillus plantarum (Peral etal. (2009), Lukic etal. (2017)). It was hypothesised that these would compete with pathogenic bacteria, modify the wound environment and promote tissue repair. However, these studies were too small to allow appropriate statistical analysis, and there has been no approval for use in a clinical setting.
The skin microbiome is a major area of research focus with respect to chronic skin conditions such as psoriasis, eczema and acne. However, comparatively little is known about how the native skin microbiome responds to burn wound trauma, despite numerous studies exploring the impact of burn wound trauma on the gut microbiome (Lima etal., 2021).
The main burn wound microbiome study performed in humans has suggested that there are no differences in microbial abundance or composition between burn sites and unaffected areas (Liu etal., 2018). Another study exploring the human burn wound microbiome suggested that the commensal microbial community was significantly altered as a result of burn wound trauma compared to controls. This study uncovered several bacterial taxa that correlated with improved clinical outcomes. However, a key limitation of this study is that it analysed a single snapshot of the microbial community at a specific time and as such gave no insights into the temporal community kinetics or the impact on the nnicrobiome at undamaged sites (Plichta etal., 2017). A more recent study of the human burn wound microbiota reported a reduction in alpha diversity within the wounds and a reduction in the abundance of common skin commensals such as Cut/bacterium acnes and Staphylococcus epidermitis. However this study was limited to only 10 patients (Lima et al., 2021). Other studies in animal models also support the hypothesis that the commensal bacteria that recolonise the burn wound can influence clinical outcomes (Sanjar et at, 2020).
C. acnes (previously known as Propionibacterium acnes) is an anaerobic, Gram-positive bacterium. It is largely commensal and can be found in the skin flora present on most healthy adult humans' skin. It is, however, also implicated in the inflammation of hair follicles, and under certain conditions, notably in adolescents, specific strains are known to be pathogenic, being associated with skin conditions such as acne vulgaris.
Embodiments of the invention relate to a composition including C. acnes, C. acnes culture supernatant, and/or a bioactive extract or metabolites obtainable from C. acnes culture/supernatant for use in a method of medical treatment, in particular for treating or preventing wound infection. The wound may be a burn.
Bioactive non-pathogenic strains could be used, potentially as an alternative to antibiotics, to prevent wound infection and promote wound healing. In embodiments, the bacterial cells themselves may not be necessary for the anti-virulence activity. Rather, the cell free supernatant that the C. acnes strain has grown in (or bioactive extracts obtainable therefrom) could be used to disrupt virulence.
The present inventors have found that infection, in particular by Gram-5 negative bacteria such as Pseudomonas aeruginosa, can be prevented by C. acnes.
An invertebrate in vivo burn wound model (Maslova etal. (2020)) was used to screen a range of different skin commensals to determine if any could prevent subsequent infection with Pseudomonas aeruginosa, a common Gram-negative opportunistic pathogen. This model has been shown to recapitulate the hallmarks of burn wound trauma and infection seen in higher models (such as mammalian models). It therefore addresses a major limitation to the development of wound probiotics, by providing an alternative to mammalian in vivo models to enable high-throughput screening of potential probiotics. From these screens, the inventors identified C. acnes as a promising candidate for a wound treatment probiotic.
C. acnes, when applied directly to a wound, can improve survival and disable virulence by P. aeruginosa, one of the most prevalent burn wound pathogens. C. acnes, and/or components produced thereby, can help prevent infection developing in wounds by disabling the mechanisms that pathogens use to establish infection.
C. acnes has previously been shown to be able to influence the skin microbiome in hair follicles through the production of cutimycin, a thiopeptide antibiotic, which has activity against Gram-positive bacteria and is capable of killing Staphylococcus species (Claesen etal. (2020)).
However, thiopeptide antibiotics are ineffective against Gram-negative bacteria.
The bacterial cells could be directly applied to the wound. Prior probiotic 5 treatment of wounds has taken the form of direct application of a probiotic to the wound bed, saturation of a standard wound dressing with the probiotic, integration of the probiotic into a gel that is applied to the wound, or the integration of the probiotic into a cream/lotion (Huseini etal. (2012), Jones et al. (2012), Peral et at (2009), DiMarzio 10 etal. (2008)). Any or all of these application methods may be used with the C. acnes probiotics and/or bioactive extracts disclosed herein as exemplified below.
It is proposed that C. acnes can be used in a number of different applications to treat or to prevent wound infection. This can include, but is not limited to, the direct application of the bacteria to the wound or the application of spent growth medium (culture supernatant) from the bacterium or the application of bioactive metabolites produced by the bacteria to the wound. The bacteria, culture supernatant or metabolites may be impregnated into a vehicle (for example, an ointment, a cream, or a wound dressing).
Embodiments of the composition may be applied to the burn or other wound in the form of an impregnated or otherwise augmented wound dressing (such as a sterile pad or compress), a lotion, ointment, gel, or a cream that is applied to the wound after injury. These applications will minimise the probability of infection developing as the mechanisms through which a pathogen can establish infection will be disabled.
A composition according to embodiments may comprise C. acnes cells (live or dead), cellular contents, cell free supernatant or bioactive components derived from the cell free supernatant. Genetic elements associated with bioactivity can be amplified and subcloned into a heterologous host for upscaled production, or genetically manipulated either through evolved or targeted nnutagenesis to increase the production of the bioactive elements or to enhance the bioactivity of the strain and/or cell free supernatant or to increase production of the bioactive components.
C. acnes compositions for use in the methods described herein can be prepared by liquid or plate culture, for example.
Preparation of liquid culture of C. acnes can include the steps of: 1) Inoculating a suitable liquid culture medium, for example, TSB, with C. acnes; and 2) Incubating at 370C in anaerobic conditions, for example for 48-72 hours.
Plate culture can include: 1) Inoculating blood agar (including, for example, TSA and horse blood) with C. acnes; and 2) Incubating in anaerobic conditions, for example for 48-72 hours.
A composition including C. acnes supernatant for use in the methods described herein can be prepared for example by a method including the following steps: 1) Preparing a liquid culture as set out above; 2) Pelleting the bacterial cells using a centrifuge; and 3) Filtering the supernatant.
The composition may be incorporated into a formulation by impregnating or otherwise combining with a vehicle such as an ointment, gel or cream. In practice, the vehicle is seeded with live or dead C. acnes cells prepared as described herein, or a component of the vehicle is C. acnes cell free supernatant or a bioactive component (e.g. metabolite) derived from the cell culture or cell free supernatant. The cells, supernatant or bioactive component may be included alone, or in any combination, with or without other anti-infective agents.
It is envisaged that a wound dressing be impregnated with a seed culture of bioactive strains of C. acnes. This would allow prolonged and stable colonisation of the wound bed by C. acnes. This wound dressing can take the form of a hydrogel, gauze, films, foams, hydrocolloids or composites augmented with C. acnes. Equally these dressings could be saturated or augmented with C. acnes cell free supernatant or the bioactive components derived from the cell free supernatant. The augmented dressings can be used to prevent infection by application to the wound immediately post-trauma. Equally they can be used to treat infection either singularly or in combination with standard antibiotic therapy.
Figures 1 to 5 illustrate some exemplary types of augmented wound dressing that can be used as a prophylactic (on an uninfected wound) or for treatment of an infected wound. Augmented wound dressings can be made by applying a composition or formulation including C. acnes, C. acnes culture supernatant, and/or a bioactive extract or metabolite obtainable from C. acnes culture and/or supernatant to a skin wound dressing, which may be of known type.
Figure 1 illustrates a simple single layer cell dressing (100). In this example, a wound dressing of known type (130) (for example, a sterile pad or compress, a hydrogel, gauze, a film, foam, hydrocolloid or composite) is impregnated or saturated with alive or dead C. acnes cells (110) to seed a wound bed.
Figure 2 illustrates a bi-layer cell dressing (100). The dressing comprises or consists of two layers: an upper layer (130) composed of a wound dressing of known type, and a lower layer (140), which has a less dense dressing. The lower layer is impregnated or saturated with alive or dead C. acnes cells (110). This dressing provides two advantages: increased protection from potential sources of infection in the upper layer and increased dispersal of the C. acnes into the wound nnicroenvironment via the less dense lower layer.
Figure 3 also illustrates a wound dressing (100) that includes C. acnes cells (110). The C. acnes cells are sealed in a nutrient permeable compartment (150) within a wound dressing of known type (130). A wound sealing membrane (160), such as a TegadermTm dressing is provided at the side of the dressing (100) to be applied to the wound. A bioactive component or metabolite produced by the C. acnes cells is able to diffuse through the wound sealing membrane into the wound bed and treat or prevent infection of the wound.
Figure 4 illustrates a bioactive wound dressing (100) that, in preferred embodiments, does not contain C. acnes cells. A dressing matrix (170) of known type (such as for example gauze or silicone dressings) is formulated or saturated with a bioactive component derived from C. acnes cell free supernatant.
Figure 5 illustrates a wound dressing (100) in which a wound dressing matrix (170) of known type has been impregnated or saturated with C. acnes cell free supernatant. For example, the matrix (170) could be a hydrogel in which the aqueous component is the C. acnes cell free supernatant.
The described probiotic finds use in a clinical capacity and also has the potential to be used as an off-the-shelf skin probiotic to treat minor cuts or burns. It takes advantage of the therapeutic potential of a commensal bacterium that is commonly found on the skin of healthy individuals.
The probiotic provides an alternative to the use of ineffective wound dressings or the topical application of antibiotics, both of which are ineffective against resistant pathogens, which cause many hospital-associated wound infections. Further, it would reduce the use of antibiotics on wound patients, potentially helping to stem the impact of antibiotic resistance.
A probiotic wound treatment based on C. acnes as described herein has 25 cost advantages, being relatively cheap to produce compared to a novel antibiotic.
Example 1 -Preparation of C. acnes culture Examples of how to prepare C. acnes for use in the methods described herein are now described.
Liquid culture 1. 15m1 of Tryptic Soy Broth (TSB) or suitable equivalent is aliquoted into 50m1 Falcon tubes.
2. -80°C cultures are inoculated into said Falcon tubes with TSB broth.
3. The Falcon tubes are placed into a hermetic chamber vertically with an Anaerogen sachet.
4. The hermetic chamber is incubated at 37°C for 48-72 hours.
Plate culture 1. Blood agar is prepared by melting Tryptic Soy Agar (TSA) and adding defibrinated horse blood in the proportion 1:19 blood:TSA. A suitable equivalent may also be used.
2. -80°C cultures are inoculated onto the blood agar plates.
3. The plates are placed into a hermetic chamber with Anaerogen sachet.
4. The hermetic chamber is incubated at 37°C for 48-72 hours.
Example 2 -Preparation of C. acnes cell free supernatant 1. 48hr Falcon tubes with grown cultures are taken out of the hermetic chamber.
2. They are spun down at 5,000 rpm for 10 minutes at room temperature in a centrifuge.
3. The supernatant is poured from these centrifuged cultures, into a syringe with a 0.2pm filter attached. The supernatant is then passed through the filter into a new sterile 50m1 Falcon tube.
4. The supernatant is then kept at room temperature for the rest of the day.
5. The supernatant is best used freshly made on the same day.
Example 3 -In vivo anti-virulence potential of C. acnes Three different strains of C. acnes (C. acnes CCUG38584 (ATCC 6922;NCTC 556), C. acnes CCUG6369 (ATCC 11828), C. acnes CCUG48370) were tested using the invertebrate in vivo burn wound model developed by Maslova et al. (2020). This enabled determination of the strain specificity of the anti-virulence effect and found that all three strains were capable of significantly reducing pathogenicity in the in vivo wound infection model.
Galleria mellonella were obtained from LiveFood UK Ltd. (Somerset, United Kingdom). Only 6th instar larvae were used for experiments, which is the life stage at which they do not require feeding. Prior to use, larvae were stored at +40C. Before the experiment, larvae were sorted into Petri dishes lined with filter paper (Whatman, Fisher, United Kingdom) at a maximum of 10 larvae per dish, and they were stored at +40C until use.
70% ethanol was used to sterilise the larval body surface. Petri dishes were left open in a sterile environment to allow for the ethanol to evaporate after sterilisation. The burn was induced by using a heated steel element embedded in insulating material to consistently achieve approx. 2mnn squared burn area. The burn instrument was heated in the middle flame of a Bunsen burner until it was red/white-hot and applied to the middle segment of G. me/lone/la's back for 4s.
The bacterial infection was induced by applying 10p1 of overnight bacterial culture, or by applying bacterial colonies. For the co-colonisation assay, the C. acnes colonies were inoculated first directly onto the wound and 10p1 of a liquid overnight culture of a pathogenic bacteria (P. aeruginosa PA14) was applied straight away on top of it.
Figure 6 illustrates infection progression in the G. me/lone/la burn wound model, demonstrating that it mimics the bacteraemia and sepsis seen in mouse models, with local tissue damage, biofilnn formation at the wound site and subsequent dissemination from the wound to deeper tissue and larval haennolynnph (blood). Over time, the G. me//one//a larvae (10) become damaged due to infection progression (30) from the burn site (20). Infection progression was seen through melanisation of the larvae and subsequent loss of movement. Larvae were considered dead if they did not respond to manual stimulation with a pipette tip.
Live and dead larvae counts were the used to create Kaplan Meier Survival curves (probablility of survival).
Figure 7 demonstrates the probiotic potential of C. acnes CCUG 38584. Topical treatment of larvae with C. acnes prior to subsequent challenge with P. aeruginosa PA14 (UCI3PP_PA14) significantly improves survival compared to untreated larvae. . Time measured in Hours. Differences in survival between PA14 only vs. CCUG 38584 significant at Log Rank p< 0.01. C. acnes CCUG_38584 alone did not have a significant impact on survival. JB represents the "just burn" control.
Figure 8 demonstrates the probiotic potential of C. acnes CCUG 48370. Topical treatment of larvae with C. acnes prior to subsequent challenge with P. aeruginosa PA14 (UCBPP_PA14) significantly improves survival compared to untreated larvae. Time measured in Hours. Differences in survival between PA14 only vs. CCUG 48370 significant at Log Rank p< 0.01. C. acnes CCUG_48370 alone did not have a significant impact on survival. JB represents the "just burn" control.
Figure 9 demonstrates the probiotic potential of C. acnes CCUG 6369. Topical treatment of larvae with C. acnes prior to subsequent challenge with P. aeruginosa PA14 significantly improves survival compared to untreated larvae. Time measured in Hours. Differences in survival between PA14 only vs. CCUG 6369 significant at Log Rank p< 0.05.
C. acnes CCUG 6369 alone did not have a significant impact on survival. JB represents the "just burn" control.
This work shows that the application of C. acnes to a burn wound can have a significant impact on improving the survival of G. me/lone//a larvae that are subsequently challenged with the burn wound pathogen P. aeruginosa (Figures 7, 8, and 9).
Example 4 -C. acnes augmented wound dressing C. acnes cells or cell free supernatant can be used in a wound dressing, and in an embodiment is particularly envisaged for a wound dressing for 5 burns. In an embodiment, such a C. acnes augmented wound dressing can be prepared as follows: 15m1 of Tryptic Soy Broth (TSB) or suitable equivalent is aliquoted into 50nnl Falcon tubes. -80°C stock cultures of the relevant C. acnes strain are inoculated into said Falcon tubes with TSB broth. The Falcon tubes are placed into a hermetic chamber vertically with an Anaerogen sachet or an equivalent anaerobic incubation chamber. The cultures are incubated at 37°C for 48-72 hours.
Following this, cultures are spun down in a centrifuge for 15 minutes at <8,000 rotations per minute. The supernatant is then removed and can be used directly to saturate a standard woven gauze (cotton or suitable alternative).
For a live culture preparation, the remaining cell pellet is resuspended in 1 ml of phosphate buffered saline solution to achieve a completely homogenous solution. This solution of live cells can then be applied directly to a standard woven cotton gauze dressing to achieve complete saturation typically (1 nnl/cm2) (Peral et at, 2009).
For optimal efficacy this dressing would then be applied immediately to the affected region of skin. This application would facilitate seeding of the wound bed with C. acnes. Alternatively, the dressing could be stored in sterile conditions that would preserve bacterial viability (4°C) for a defined period of time before being applied to the wound. It is suggested that a fresh dressing be applied daily and fresh bacterial cultures used for each dressing.
The application of C. acnes as a probiotic to wounds (and/or more specifically to burn wounds) to prevent infection, in particular by common Gram-negative opportunistic pathogens has not previously been described.
The principle supporting this application is that C. acnes can be used as probiotics and applied to wounds to prevent infection and to promote healing. It has been demonstrated that the most common burn wound pathogen P. aeruginosa's virulence is significantly disrupted when C. acnes is applied to a burn wound prior to pathogen challenge.
It is envisaged that the active component of C. acnes bioactivity and/or the genes responsible for this, could be used in therapeutics rather than whole bacteria. Upscaled production of the bioactive component could be achieved by cloning the genes responsible for the activity into another commensal bacterium to augment their activity or by cloning them into a heterologous expression host using known methods.
All optional and preferred features and modifications of the described embodiments and dependent claims are usable in all aspects of the invention taught herein. Furthermore, the individual features of the dependent claims, as well as all optional and preferred features and modifications of the described embodiments are combinable and interchangeable with one another.
It will be appreciated by those skilled in the art that changes could be made to the embodiments and examples described above without departing from the broad inventive concept. It is understood, therefore, that this invention is not limited to the particular embodiments disclosed, but it is intended to cover modifications within the spirit and scope of the present invention as defined by the claims.
References Claesen et al. (2020) Sci. Transt Med. 12, eaay5445 DiMarzio et al. (2008) Int. J Immunopathol. Pharmacol. 21, 137-43.
Huseini etal. (2012) Burns 38, 719-23.
Jones etal. (2012) Int. Wound J. 9, 330-43.
Lima et al. (2021) Sci. Rep. 11, 10667 Liu etal. (2018) Wound Repair Regen. 26, 182-91 Lukic etal. (2017) Wound Repair Regen. 25, 912-22 Maslova et al. (2020) Front. Microbiol. 11, 998 Peral etal. (2009) Int. Wound J. 6, 73-81 Plichta et al. (2017) Shock 48, 441-8 Sanjar et al. (2020) J. Burn Care Res. 41, 347-58
Claims (10)
- CLAIMS1. A composition including Cut/bacterium acnes, Cut/bacterium acnes culture supernatant, and/or a bioactive extract or metabolite obtainable 5 from Cut/bacterium acnes culture and/or supernatant for use in a method of medical treatment.
- 2. A composition including C. acnes, C. acnes culture supernatant, and/or a bioactive extract or metabolite obtainable from C. acnes culture and/or supernatant for use in a method of treating or preventing wound infection.
- 3. A composition for use as claimed in claim 1 or 2, wherein the wound is a burn.
- 4. A composition for use as claimed in claim 1, 2 or 3, wherein the method of medical treatment is treatment or prevention of infection by Gram-negative bacteria.
- 5. A composition for use as claimed in any preceding claim, wherein the method of medical treatment is treatment or prevention of infection by Pseudomonas aeruginosa.
- 6. A formulation for application to a human skin wound including a composition as claimed in any preceding claim, a therapeutically effective amount of Cut/bacterium acnes, Cut/bacterium acnes culture supernatant, and/or a bioactive extract or metabolite obtainable from Cut/bacterium acnes culture and/or supernatant in combination with a dernnatologically compatible carrier.
- 7. A formulation as claimed in claim 6, wherein the carrier is an ointment, a gel, or a cream.
- 8. An augmented wound dressing including a composition as claimed in any of claims 1 to 5 or a formulation as claimed in claim 6 or 7.
- 9. A method of making a formulation as claimed in claim 6, including incorporating a therapeutically effective amount of a composition as claimed in any of claims 1 to 5, or of Cut/bacterium acnes, Cutibacterium acnes culture supernatant, and/or a bioactive extract or metabolite obtainable from Cut/bacterium acnes culture and/or supernatant, into a dermatologically compatible carrier.
- 10. A method of making an augmented wound dressing as claimed in claim 8, including applying a composition as claimed in any of claims 1 to 5 or a formulation as claimed in claim 6 or 7 to a dressing for treating a skin wound.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB2214521.3A GB2623078A (en) | 2022-10-03 | 2022-10-03 | Prevention and/or treatment of wound infection |
PCT/GB2023/052506 WO2024074803A1 (en) | 2022-10-03 | 2023-09-27 | Prevention and/or treatment of wound infection |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB2214521.3A GB2623078A (en) | 2022-10-03 | 2022-10-03 | Prevention and/or treatment of wound infection |
Publications (2)
Publication Number | Publication Date |
---|---|
GB202214521D0 GB202214521D0 (en) | 2022-11-16 |
GB2623078A true GB2623078A (en) | 2024-04-10 |
Family
ID=84000064
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB2214521.3A Pending GB2623078A (en) | 2022-10-03 | 2022-10-03 | Prevention and/or treatment of wound infection |
Country Status (2)
Country | Link |
---|---|
GB (1) | GB2623078A (en) |
WO (1) | WO2024074803A1 (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4647456A (en) * | 1980-03-25 | 1987-03-03 | Dr. Madaus & Co. | Methods of increasing tolerance to radiotherapy and chemotherapy using propioni bacteria |
US20180021452A1 (en) * | 2016-07-22 | 2018-01-25 | National Central University | Bacterium-containing hydrogel and method of making the same |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT202000003233A1 (en) * | 2020-02-18 | 2021-08-18 | Aileens Pharma S R L | BACTERIAL STRAIN AND ITS MEDICAL USES |
JP2023514414A (en) * | 2020-02-21 | 2023-04-05 | オリジム・バイオテクノロジー・ゲー・エム・ベー・ハー | Prophylactic and therapeutic immunization against Propionibacterium acnes |
AU2021297215A1 (en) * | 2020-06-23 | 2023-02-09 | Crown Laboratories, Inc. | Probiotic skin formulations |
-
2022
- 2022-10-03 GB GB2214521.3A patent/GB2623078A/en active Pending
-
2023
- 2023-09-27 WO PCT/GB2023/052506 patent/WO2024074803A1/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4647456A (en) * | 1980-03-25 | 1987-03-03 | Dr. Madaus & Co. | Methods of increasing tolerance to radiotherapy and chemotherapy using propioni bacteria |
US20180021452A1 (en) * | 2016-07-22 | 2018-01-25 | National Central University | Bacterium-containing hydrogel and method of making the same |
Non-Patent Citations (4)
Title |
---|
Infection and Immunity, vol. 12, no. 6, 1975, Sher et al., Effects of BCG, Corynebacterium parvum, and Methanol-Extraction Residue in the Reduction of Mortality from Staphylococcus aureus and Candida albicans Infections in Immunosuppressed mice, p. 1325-1330. * |
PLOS ONE, vol. 8, no. 2, 2013, Shu, M. et al., "Fermentation of Propionibacterium acnes, a Commensal Bacterium in the Human Skin Microbiome, as Skin Probiotics against Methicillin-Resistant Staphylococcus aureus", e55380, pages 1-11. * |
Surgery, vol. 87, no. 1, 1980, Calhoun, K. et al., "Corynebacterium parvum: immunomodulation in local bacterial infections.", p. 52-58. * |
Surgery, vol. 89, no. 2, 1981, Stinnett, JD. et al., "Improved survival in severely burned animals using intravenous Corynebacterium parvum vaccine post injury.", p. 237-242. * |
Also Published As
Publication number | Publication date |
---|---|
WO2024074803A1 (en) | 2024-04-11 |
GB202214521D0 (en) | 2022-11-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Mullai et al. | Bactericidal activity of different types of honey against clinical and environmental isolates of Pseudomonas aeruginosa | |
Savitskaya et al. | Antimicrobial and wound healing properties of a bacterial cellulose based material containing B. subtilis cells | |
Demling et al. | The rate of re-epithelialization across meshed skin grafts is increased with exposure to silver | |
ZAKARIA et al. | Antimicrobial activity of Piper ribesoides root extract against Staphylococcus aureus | |
BRENTANO et al. | Bacteriology of large human burns treated with silver nitrate | |
Hiruma et al. | Hyperthermic treatment of chromomycosis with disposable chemical pocket warmers: report of a successfully treated case, with a review of the literature | |
Guenova et al. | Banana leaves as an alternative wound dressing | |
CN104382685A (en) | Method for preparing human vaginal microecological preparation-probiotics condom | |
Kagan et al. | The skin bank | |
Nagoba et al. | Acetic acid treatment of pseudomonal wound infections | |
US11766465B2 (en) | External composition for wound healing containing lactobacillus fermentation product and method for promoting wound healing using the same | |
Loc-Carrillo et al. | 13 Phage Therapy of Wounds and Related Purulent Infections | |
Hassanain et al. | Antimicrobial effect of Malaysian honey on some human pathogens: An in vitro study | |
Bazaz et al. | Evaluation of antimicrobial and healing activities of frog skin on guinea pigs wounds | |
GB2623078A (en) | Prevention and/or treatment of wound infection | |
RU2613708C2 (en) | Ways of acne treatment | |
Marcos-Tejedor et al. | The bacteriostatic effect of controlled-flux electrolyzed acidic solution on healthy hallucal skin | |
Khanafari et al. | Combined application of microbial cellulose and papaver macrostomum extract on bedsore microorganisms | |
Fader et al. | Sodium hypochlorite decontamination of split-thickness cadaveric skin infected with bacteria and yeast with subsequent isolation and growth of basal cells to confluency in tissue culture | |
CHAMBERS et al. | A fungistatic strain of Bacillus subtilis isolated from normal toes | |
JPH06135843A (en) | Agent for skin | |
Ali et al. | Healing of guinea pig injures contaminated with Pseudomonas aeruginosa by using 0.7 Hz square pulsed magnetic field (new method) | |
Igbinosa et al. | Combination of Ageratum conyzoides leaf extracts with antibiotics against Staphylococcus aureus and Pseudomonas aeruginosa isolated from wound infection | |
Melnyk et al. | Microbiological aspects of the examination of the 140-year-old embalmed body of NI Pirogov | |
Bhuyan et al. | Antimicrobial activity of endophytic fungi isolated from a traditionally important plant of NE India-Litsea chinensis Lam. |